Arcellx (NASDAQ:ACLX) Downgraded by Evercore to “Hold”

Arcellx (NASDAQ:ACLX) was downgraded by stock analysts at Evercore from a “strong-buy” rating to a “hold” rating in a research report issued on Monday,Zacks.com reports.

ACLX has been the topic of a number of other reports. UBS Group lowered Arcellx from a “buy” rating to a “neutral” rating and lifted their price target for the stock from $100.00 to $115.00 in a report on Tuesday. William Blair lowered Arcellx from a “strong-buy” rating to a “hold” rating in a research report on Monday. Leerink Partners reissued a “market perform” rating and issued a $115.00 price target on shares of Arcellx in a report on Tuesday. Wolfe Research initiated coverage on shares of Arcellx in a report on Tuesday, November 18th. They set a “peer perform” rating for the company. Finally, Stifel Nicolaus reaffirmed a “hold” rating and issued a $115.00 price objective (down from $127.00) on shares of Arcellx in a research report on Monday. Two investment analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Arcellx presently has an average rating of “Hold” and an average price target of $111.64.

Arcellx Stock Performance

Shares of ACLX stock opened at $113.71 on Monday. The company has a market capitalization of $6.57 billion, a price-to-earnings ratio of -28.93 and a beta of 0.36. Arcellx has a 52-week low of $47.86 and a 52-week high of $114.26. The company has a 50-day simple moving average of $68.84 and a two-hundred day simple moving average of $75.38.

Insider Transactions at Arcellx

In other Arcellx news, insider Christopher Heery sold 5,882 shares of the company’s stock in a transaction dated Wednesday, January 14th. The shares were sold at an average price of $68.51, for a total transaction of $402,975.82. Following the sale, the insider directly owned 23,749 shares of the company’s stock, valued at $1,627,043.99. This represents a 19.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In the last quarter, insiders sold 19,450 shares of company stock valued at $1,283,477. Insiders own 8.35% of the company’s stock.

Institutional Trading of Arcellx

Several hedge funds and other institutional investors have recently modified their holdings of the business. T. Rowe Price Investment Management Inc. lifted its stake in shares of Arcellx by 66.2% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 10,560,425 shares of the company’s stock valued at $688,540,000 after buying an additional 4,208,069 shares in the last quarter. Vestal Point Capital LP raised its holdings in Arcellx by 134.0% during the 4th quarter. Vestal Point Capital LP now owns 2,925,000 shares of the company’s stock valued at $190,710,000 after acquiring an additional 1,675,000 shares during the period. Paradigm Biocapital Advisors LP raised its holdings in Arcellx by 23.1% during the 4th quarter. Paradigm Biocapital Advisors LP now owns 5,724,016 shares of the company’s stock valued at $373,206,000 after acquiring an additional 1,075,000 shares during the period. Decheng Capital LLC lifted its position in shares of Arcellx by 995.2% during the second quarter. Decheng Capital LLC now owns 547,609 shares of the company’s stock worth $36,060,000 after acquiring an additional 497,609 shares in the last quarter. Finally, State Street Corp boosted its holdings in shares of Arcellx by 31.0% in the fourth quarter. State Street Corp now owns 1,998,503 shares of the company’s stock worth $130,302,000 after acquiring an additional 472,476 shares during the period. Institutional investors own 96.03% of the company’s stock.

Key Stories Impacting Arcellx

Here are the key news stories impacting Arcellx this week:

• Positive Sentiment: Gilead Sciences agreed to acquire Arcellx for $115.00 per share in cash plus one contingent value right worth $5.00 if milestones are met, implying up to ~$7.8 billion — a takeover premium that drove a large rally. Gilead acquisition release
• Positive Sentiment: Market reaction: the deal triggered a premarket surge (roughly 75–80% intraday move at announcement) and sharply elevated trading volumes as the market re‑priced ACLX to reflect the cash consideration. Reuters coverage
• Neutral Sentiment: HC Wainwright updated FY2030 EPS expectations materially (analyst projects $4.95/sh) but kept a “Neutral” rating and $115 price objective — effectively aligned with the deal price and not implying incremental upside beyond the offer. MarketBeat report
• Negative Sentiment: Multiple brokerages downgraded ACLX to “hold”/”equal weight” (Truist, Baird, Canaccord, Needham, Wells Fargo, Citigroup), signaling limited upside above the deal price and reducing buy‑side conviction. Example coverage: Truist/Benzinga. Benzinga downgrades roundup
• Negative Sentiment: Several law firms (Kahn Swick & Foti, Halper Sadeh, Ademi, Monteverde) announced investigations into whether the $115 + $5 CVR consideration is fair — potential litigation could seek a higher price, delay closing or increase transaction risk/uncertainty. KSF investor alert

Arcellx Company Profile

Arcellx, Inc (NASDAQ: ACLX) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation cell therapies for oncology and autoimmune diseases. The company’s proprietary ARC-SparX™ platform is designed to enable precise control over cell-surface receptor activation and to improve the safety, efficacy and durability of adoptive cell therapies. Leveraging this technology, Arcellx engineers immune cells with modular antigen-binding domains that can be exchanged to target a variety of disease-associated markers.

The company’s pipeline comprises multiple wholly owned programs in hematologic malignancies and solid tumors at various stages of preclinical and clinical development.